Apnimed’s oral sleep apnoea therapy AD109 has met the primary endpoint in a Phase III trial, with hopes to file for approval of the drug in early 2026. In the Phase III SynAIRgy trial (NCT05813275), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results